ADA/EASD recommends adding sulfonylurea (oral antidiabetic) to insulin as first-line combination therapy for low-income type 2 DM patients without a history of ASCVD and chronic kidney disease (CKD) [7]. This evidence concerns the gene INS and atherosclerosis.